Pancreatic Cancer Research

ResearcherStanford MedicineNo recent work listed

Margaret M. Kozak

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0734-9427; OpenAlex author ID A5045122246. Sources: OpenAlex.

Their work

Papers
12
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2016: 1 paper · 2017: 3 papers · 2018: 3 papers · 2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper

Papers 12

  1. Spatially Resolved Single-Cell Assessment of Pancreatic Cancer Expression Subtypes Reveals Co-expressor Phenotypes and Extensive Intratumoral Heterogeneity. Co-author DOI 10.1158/0008-5472.can-22-3050↗
  2. Neoadjuvant Chemotherapy Is Associated with Altered Immune Cell Infiltration and an Anti-Tumorigenic Microenvironment in Resected Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1125↗
  3. Composition, Spatial Characteristics, and Prognostic Significance of Myeloid Cell Infiltration in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3141↗
  4. Insulin-Like Growth Factor-1 Receptor Expression and Disease Recurrence and Survival in Patients with Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1055-9965.epi-19-1315↗
  5. Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer. Co-author DOI 10.1038/s41436-018-0009-5↗
  6. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamaoncol.2017.3420↗
  7. Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance. Co-author DOI 10.1038/s41598-018-32159-x↗
  8. Albumin and Neutrophil-Lymphocyte Ratio (NLR) Predict Survival in Patients With Pancreatic Adenocarcinoma Treated With SBRT. Co-author DOI 10.1097/coc.0000000000000263↗
  9. A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.09.007↗
  10. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Co-author DOI 10.1038/bjc.2017.349↗
  11. BLIMP1 Induces Transient Metastatic Heterogeneity in Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-17-0250↗
  12. Statin and Metformin Use Prolongs Survival in Patients With Resectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000470↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Albert C. Koong · 12 shared papers, 2016–2023 · strength 0.88
  2. Daniel Tandel Chang · 10 shared papers, 2016–2023 · strength 0.74
  3. Chen Yuan · 7 shared papers, 2017–2023 · strength 0.55
  4. Richard Francis Dunne · 7 shared papers, 2017–2023 · strength 0.55
  5. Thomas E. Clancy · 7 shared papers, 2017–2023 · strength 0.55
  6. Douglas Adam Rubinson · 7 shared papers, 2017–2023 · strength 0.55
  7. Vicente Morales‐Oyarvide · 7 shared papers, 2017–2023 · strength 0.55
  8. Aram F. Hezel · 7 shared papers, 2017–2023 · strength 0.55
  9. Brian Matthew Wolpin · 7 shared papers, 2017–2023 · strength 0.55
  10. Jonathan Andrew Nowak · 7 shared papers, 2017–2023 · strength 0.55
  11. Andrew J. Aguirre · 6 shared papers, 2018–2023 · strength 0.50
  12. David C. Linehan · 6 shared papers, 2017–2023 · strength 0.47
  13. Andressa Dias Costa · 4 shared papers, 2020–2023 · strength 0.39
  14. Kimberly J. Perez · 4 shared papers, 2019–2023 · strength 0.36
  15. Charles S. Fuchs · 5 shared papers, 2017–2021 · strength 0.33
  16. Jiping Wang · 3 shared papers, 2021–2023 · strength 0.31
  17. Hannah L. Williams · 3 shared papers, 2021–2023 · strength 0.31
  18. Sara A. Väyrynen · 3 shared papers, 2021–2023 · strength 0.31
  19. Kimmie Ng · 4 shared papers, 2017–2022 · strength 0.28
  20. William C. Hahn · 3 shared papers, 2018–2023 · strength 0.23
  21. Harshabad Singh · 2 shared papers, 2022–2023 · strength 0.22
  22. Joseph Douglas Mancias · 2 shared papers, 2022–2023 · strength 0.22
  23. James M. Cleary · 2 shared papers, 2022–2023 · strength 0.22
  24. Ana Babić · 3 shared papers, 2017–2020 · strength 0.17
  25. Andrea J. Bullock · 3 shared papers, 2017–2019 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.